Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H23N3O2.ClH |
| Molecular Weight | 313.823 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCNC(=O)C1=CC=C(NC(C)=O)C=C1
InChI
InChIKey=IYEWBJUCJHKLHD-UHFFFAOYSA-N
InChI=1S/C15H23N3O2.ClH/c1-4-18(5-2)11-10-16-15(20)13-6-8-14(9-7-13)17-12(3)19;/h6-9H,4-5,10-11H2,1-3H3,(H,16,20)(H,17,19);1H
Acecainide (N-acetylprocainamide), the N-acetylated metabolite of procainamide, is a Class III antiarrhythmic agent. Acecainide exerts cardiac anticholinergic effect. It elicits smooth muscle relaxation mainly through the activation of plasma membrane K+ channels. Acecainide markedly reduced premature ventricular beats and prevented induction of ventricular tachycardia. Acecainide appears to offer advantages over procainamide, particularly with respect to the reduced formation of antinuclear antibodies. Acecainide development has been discontinued.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. | 1976 Nov-Dec |
|
| Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. | 1977 Jul |
|
| Polymorphic ventricular tachycardia and ventricular fibrillation due to N-acetyl procainamide. | 1985 Jan 1 |
|
| Study of procainamide hapten-specific antibodies in rabbits and humans. | 1993 Nov |
|
| Quantitative estimation of renal clearance of N-acetylprocainamide in rats with various experimental acute renal failure. | 2001 Jun |
|
| Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle. | 2001 Mar 9 |
|
| cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. | 2002 Jul |
|
| The prince and the pauper. A tale of anticancer targeted agents. | 2008 Oct 23 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47793
Created by
admin on Fri Dec 15 15:26:42 GMT 2023 , Edited by admin on Fri Dec 15 15:26:42 GMT 2023
|
||
|
NCI_THESAURUS |
C93038
Created by
admin on Fri Dec 15 15:26:42 GMT 2023 , Edited by admin on Fri Dec 15 15:26:42 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
B9K738KX14
Created by
admin on Fri Dec 15 15:26:42 GMT 2023 , Edited by admin on Fri Dec 15 15:26:42 GMT 2023
|
PRIMARY | |||
|
34118-92-8
Created by
admin on Fri Dec 15 15:26:42 GMT 2023 , Edited by admin on Fri Dec 15 15:26:42 GMT 2023
|
PRIMARY | |||
|
m1291
Created by
admin on Fri Dec 15 15:26:42 GMT 2023 , Edited by admin on Fri Dec 15 15:26:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID1045748
Created by
admin on Fri Dec 15 15:26:42 GMT 2023 , Edited by admin on Fri Dec 15 15:26:42 GMT 2023
|
PRIMARY | |||
|
C75126
Created by
admin on Fri Dec 15 15:26:42 GMT 2023 , Edited by admin on Fri Dec 15 15:26:42 GMT 2023
|
PRIMARY | |||
|
CHEMBL1097
Created by
admin on Fri Dec 15 15:26:42 GMT 2023 , Edited by admin on Fri Dec 15 15:26:42 GMT 2023
|
PRIMARY | |||
|
759312
Created by
admin on Fri Dec 15 15:26:42 GMT 2023 , Edited by admin on Fri Dec 15 15:26:42 GMT 2023
|
PRIMARY | |||
|
71417
Created by
admin on Fri Dec 15 15:26:42 GMT 2023 , Edited by admin on Fri Dec 15 15:26:42 GMT 2023
|
PRIMARY | |||
|
251-831-2
Created by
admin on Fri Dec 15 15:26:42 GMT 2023 , Edited by admin on Fri Dec 15 15:26:42 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
